Holen Sie sich die Stockscreener-App
76.63
0.17%
0.13
Handel nachbörslich:
76.75
0.12
+0.16%
Tempus Ai Inc Aktie (TEM) Neueste Nachrichten
Tempus AI (NASDAQ:TEM) Shares Down 6.1%Here's Why - MarketBeat
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 - Business Wire
What Does Today’s Signal Mean for Tempus AI (NASDAQ:TEM)? - Kalkine Media
$Tempus AI (TEM.US)$ - Moomoo
A trading plan governed the sale of 10,281 Tempus AI (TEM) shares by its diagnostics CEO at $85 each. - Stock Titan
Tempus AI, Inc. Class A Bonds — Corporate Bond Rates - TradingView
Why Tempus AI (TEM) Stock Is Down Today - Quiver Quantitative
Best Artificial Intelligence Stocks To ConsiderSeptember 29th - MarketBeat
Current ratio of Tempus AI, Inc. Class A – HAN:F3M - TradingView
Tempus AI Has Three FDA-Cleared ECG Algorithms - FourWeekMBA
Tempus AI receives FDA clearance for heart valve AI tool - Investing.com
Tempus AI receives FDA clearance for heart valve AI tool By Investing.com - Investing.com India
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation - Business Wire
Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike (ARKK:BATS) - Seeking Alpha
Tempus AI CEO Ryan Fukushima sells $49,000 in stock By Investing.com - Investing.com South Africa
Tempus AI CEO Lefkofsky sells $16.1m common stock By Investing.com - Investing.com South Africa
Tempus AI CEO Lefkofsky sells $16.1m common stock - Investing.com
Tempus AI CEO Ryan Fukushima sells $49,000 in stock - Investing.com
Tempus AI CAO Ryan Bartolucci sells $529,650 in stock - Investing.com
Form 4 Tempus AI Inc For: 27 September By Investing.com - Investing.com Canada
Tempus AI EVP Andrew Polovin sells 2,951 shares for $221,325 - Investing.com
Form 144 Tempus AI For: 27 September - Investing.com India
Artificial Intelligence Stocks To Watch TodaySeptember 26th - MarketBeat
Tempus AI gets FDA clearance for pulmonary hypertension AI tool - scanx.trade
Tempus AI, Inc. Class A Ignites Investor Hype - TipRanks
Form 144 Tempus AI For: 26 September - Investing.com India
Form 144 Tempus AI For: 26 September By Investing.com - Investing.com Australia
Artificial Intelligence Stocks To Follow TodaySeptember 25th - MarketBeat
Tempus AI, Inc. (TEM) options chain - Yahoo Finance Australia
Tempus AI, Inc. (TEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Leica Biosystems brings Tempus pathology products to Aperio AI Store, accelerating AI-powered capabilities for oncology research - News-Medical
AI in Clinical Trials Market Set for Transformative Growth Through 2040, Unlocking Opportunities Across Trial Phases, Therapeutic Areas, End Users and Key Global Regions - GlobeNewswire Inc.
#Day 10Looking to Take Profit on my tempus - Moomoo
Tempus AI (NASDAQ:TEM) CEO Sells 250,000 Shares of Company Stock - MarketBeat
RXRX Stock Rises As Tempus AI Deal Resets Growth Story - StocksToTrade
Tempus AI(TEM.US) 10% Shareholder Sells US$19.37 Million in Common Stock - moomoo.com
Tempus AI CEO-linked entities sell 250,000 shares - Stock Titan
Tempus AI Inc Stock (TEM) Closed Up by 7.38% on Sep 24: What Investors Need To Know - TradingKey
Tempus AI (NASDAQ:TEM) Trading 6.1% HigherTime to Buy? - MarketBeat
Tempus AI Soars As Wall Street Bets On Data - TipRanks
Promising Artificial Intelligence Stocks To ConsiderSeptember 24th - MarketBeat
Tempus AI Chief Accounting Officer Sells $529,650 of Stock - The Globe and Mail
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4 - finance.yahoo.com
Cathie Wood’s ARK sells Tempus AI stock, buys Scribe Therapeutics By Investing.com - Investing.com South Africa
Cathie Wood’s ARK sells Tempus AI stock, buys Scribe Therapeutics - Investing.com
Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test - Yahoo Finance
Tempus AI Stock Price: TEM Stock Chart, Market Cap & News Today - CoinGecko
Tempus AI (NASDAQ:TEM) Upgraded by The Goldman Sachs Group to Hold Rating - MarketBeat
Tempus AI: High Risk, But With A Great Cause (NASDAQ:TEM) - Seeking Alpha
Goldman Sachs initiates coverage of Tempus AI (TEM.US) with a Neutral rating: Diagnostic business to benefit from reimbursement tailwinds, while data contracts enter a "validation phase" - moomoo.com
Tempus AI: Data And Applications Will Unlock More Upside (NASDAQ:TEM) - Seeking Alpha
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion - MarketBeat
Tempus AI Fails to Trim Guardant Lawsuit Over Diagnostic Tests - news.bloomberglaw.com
A data partnership shifts from potential $84 million in two-year fees to $42 million in committed payments over three - Stock Titan
Recursion Pharmaceuticals, Inc. Grants Tempus Ai, Inc. Non-Exclusive License for Rna Foundation Model - marketscreener.com
Tempus AI, Recursion Extend Data License, Amend Fee Structure - moomoo.com
Tempus extends Recursion data partnership through 2029 By Investing.com - Investing.com Nigeria
Tempus AI: Market Is Hyping On An Uncertain Number (NASDAQ:TEM) - Seeking Alpha
Goldman Sachs initiates Tempus AI stock coverage with neutral rating By Investing.com - Investing.com Australia
5.34%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):